Advertisement
Screener

Keros Therapeutics, Inc. (KROS) Weighted Average Number of Shares Outstanding, Basic and Diluted

2.8 / 5 stars · 68/120 Roast Me

Keros Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Basic and Diluted

Keros Therapeutics, Inc. (KROS) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 23.23 million shares for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-06.

Discontinued › Income Statement › Earnings Per Share

us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2021-05-06

  • Keros Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-03-31 was 23.23M shares, a 835.16% increase year-over-year.
  • Keros Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-12-31 was 21.67M shares, a 796.35% increase year-over-year.
  • Keros Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-09-30 was 20.18M shares, a 761.19% increase year-over-year.
  • Keros Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-06-30 was 17.62M shares, a 670.26% increase year-over-year.
  • Keros Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2020 was 15.51M shares, a 566.41% increase from fiscal 2019.
  • Keros Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2019 was 2.33M shares.
Period endWeighted Average Number of Shares Outstanding, Basic and Diluted 3 monthWeighted Average Number of Shares Outstanding, Basic and Diluted 6 monthWeighted Average Number of Shares Outstanding, Basic and Diluted 9 monthWeighted Average Number of Shares Outstanding, Basic and Diluted 12 month
2021-03-3123.23M shares
10-Q · filed 2021-05-06
22.45M shares
derived: average of 2 quarters · filed 2021-05-06
21.69M shares
derived: average of 3 quarters · filed 2021-05-06
20.67M shares
derived: average of 4 quarters · filed 2021-05-06
2020-12-3121.67M shares
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25
20.92M shares
derived: average of 2 quarters · filed 2021-03-25
19.82M shares
derived: average of 3 quarters · filed 2021-03-25
15.51M shares
10-K · filed 2021-03-25
2020-09-3020.18M shares
10-Q · filed 2020-11-10
18.90M shares
derived: average of 2 quarters · filed 2020-11-10
13.45M shares
10-Q · filed 2020-11-10
10.68M shares
derived: average of 4 quarters · filed 2021-05-06
2020-06-3017.62M shares
10-Q · filed 2020-08-13
10.05M shares
10-Q · filed 2020-08-13
7.51M shares
derived: average of 3 quarters · filed 2021-05-06
6.22M shares
derived: average of 4 quarters · filed 2021-05-06
2020-03-312.48M shares
10-Q · filed 2021-05-06
2.45M shares
derived: average of 2 quarters · filed 2021-05-06
2.41M shares
derived: average of 3 quarters · filed 2021-05-06
2.38M shares
derived: average of 4 quarters · filed 2021-05-06
2019-12-312.42M shares
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25
2.38M shares
derived: average of 2 quarters · filed 2021-03-25
2.35M shares
derived: average of 3 quarters · filed 2021-03-25
2.33M shares
10-K · filed 2021-03-25
2019-09-302.34M shares
10-Q · filed 2020-11-10
2.32M shares
derived: average of 2 quarters · filed 2020-11-10
2.30M shares
10-Q · filed 2020-11-10
2019-06-302.29M shares
10-Q · filed 2020-08-13
2.27M shares
10-Q · filed 2020-08-13
2019-03-312.26M shares
10-Q · filed 2020-05-22

Similar stocks

Stock NameCountryMarket CapPE Ratio
Cartesian Therapeutics, Inc. (RNAC)United States$0.231B-2.04
NATURES SUNSHINE PRODUCTS INC (NATR)United States$0.228B20.51
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
Whitehawk Therapeutics, Inc. (WHWK)United States$0.221B
Eledon Pharmaceuticals, Inc. (ELDN)United States$0.219B-3.23
Camp4 Therapeutics Corp (CAMP)United States$0.240B-2.12
MACROGENICS INC (MGNX)United States$0.242B-20.11
Cue Biopharma, Inc. (CUE)United States$0.243B-1.01
Entrada Therapeutics, Inc. (TRDA)United States$0.243B-1.73